P16 methylation increases the sensitivity of cancer cells to the CDK4/6 inhibitor palbociclib
出版年份 2019 全文链接
标题
P16 methylation increases the sensitivity of cancer cells to the CDK4/6 inhibitor palbociclib
作者
关键词
-
出版物
PLoS One
Volume 14, Issue 10, Pages e0223084
出版商
Public Library of Science (PLoS)
发表日期
2019-10-26
DOI
10.1371/journal.pone.0223084
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Direct CDKN2 modulation of CDK4 alters target engagement of CDK4 inhibitor drugs.
- (2019) Jennifer L Green et al. MOLECULAR CANCER THERAPEUTICS
- Coordinated transcription of ANRIL and P16 genes is silenced by P16 DNA methylation
- (2018) Ying Gan et al. Chinese Journal of Cancer Research
- FDA Approval: Ribociclib for the Treatment of Postmenopausal Women with Hormone Receptor–Positive, HER2-Negative Advanced or Metastatic Breast Cancer
- (2018) Anand Shah et al. CLINICAL CANCER RESEARCH
- Abemaciclib: a CDK4/6 inhibitor for the treatment of HR+/HER2– advanced breast cancer
- (2018) Silvia Paola Corona et al. Drug Design Development and Therapy
- MALAT1–miR663a negative feedback loop in colon cancer cell functions through direct miRNA–lncRNA binding
- (2018) Wei Tian et al. Cell Death & Disease
- Arrested Developments: CDK4/6 Inhibitor Resistance and Alterations in the Tumor Immune Microenvironment
- (2018) Jessica L.F. Teh et al. CLINICAL CANCER RESEARCH
- Cyclin-dependent protein serine/threonine kinase inhibitors as anticancer drugs
- (2018) Robert Roskoski PHARMACOLOGICAL RESEARCH
- CDK 4/6 Inhibitors as Single Agent in Advanced Solid Tumors
- (2018) Francesco Schettini et al. Frontiers in Oncology
- Cell-Cycle Therapeutics Come of Age
- (2017) Matthew Ingham et al. JOURNAL OF CLINICAL ONCOLOGY
- Biomarker analyses from the phase 3 PALOMA-2 trial of palbociclib (P) with letrozole (L) compared with placebo (PLB) plus L in postmenopausal women with ER + /HER2– advanced breast cancer (ABC)
- (2016) R. Finn et al. ANNALS OF ONCOLOGY
- A Phase I Study of the Cyclin-Dependent Kinase 4/6 Inhibitor Ribociclib (LEE011) in Patients with Advanced Solid Tumors and Lymphomas
- (2016) J. R. Infante et al. CLINICAL CANCER RESEARCH
- Treating cancer with selective CDK4/6 inhibitors
- (2016) Ben O'Leary et al. Nature Reviews Clinical Oncology
- Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer
- (2016) Gabriel N. Hortobagyi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Efficacy and Safety of Abemaciclib, an Inhibitor of CDK4 and CDK6, for Patients with Breast Cancer, Non-Small Cell Lung Cancer, and Other Solid Tumors
- (2016) A. Patnaik et al. Cancer Discovery
- Implications of Genetic and Epigenetic Alterations of CDKN2A (p16 INK4a ) in Cancer
- (2016) Ran Zhao et al. EBioMedicine
- FDA Approval: Palbociclib for the Treatment of Postmenopausal Patients with Estrogen Receptor-Positive, HER2-Negative Metastatic Breast Cancer
- (2015) J. A. Beaver et al. CLINICAL CANCER RESEARCH
- The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study
- (2015) Richard S Finn et al. LANCET ONCOLOGY
- The history and future of targeting cyclin-dependent kinases in cancer therapy
- (2015) Uzma Asghar et al. NATURE REVIEWS DRUG DISCOVERY
- Targeting CDK4 and CDK6: From Discovery to Therapy
- (2015) C. J. Sherr et al. Cancer Discovery
- CDK 4/6 Inhibitor Palbociclib (PD0332991) in Rb+ Advanced Breast Cancer: Phase II Activity, Safety, and Predictive Biomarker Assessment
- (2014) A. DeMichele et al. CLINICAL CANCER RESEARCH
- Loss ofCDKN2Aexpression is a frequent event in primary invasive melanoma and correlates with sensitivity to the CDK4/6 inhibitor PD0332991 in melanoma cell lines
- (2014) Richard J. Young et al. Pigment Cell & Melanoma Research
- Cdks, cyclins and CKIs: roles beyond cell cycle regulation
- (2013) S. Lim et al. DEVELOPMENT
- The p16-Specific Reactivation and Inhibition of Cell Migration Through Demethylation of CpG Islands by Engineered Transcription Factors
- (2012) Baozhen Zhang et al. HUMAN GENE THERAPY
- Systematic identification of genomic markers of drug sensitivity in cancer cells
- (2012) Mathew J. Garnett et al. NATURE
- The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity
- (2012) Jordi Barretina et al. NATURE
- p16-Cdk4-Rb axis controls sensitivity to a cyclin-dependent kinase inhibitor PD0332991 in glioblastoma xenograft cells
- (2012) L. Cen et al. NEURO-ONCOLOGY
- A 115-bp MethyLight assay for detection of p16 (CDKN2A) methylation as a diagnostic biomarker in human tissues
- (2011) Jing Zhou et al. BMC Medical Genetics
- Hallmarks of Cancer: The Next Generation
- (2011) Douglas Hanahan et al. CELL
- Expression of p16 and Retinoblastoma Determines Response to CDK4/6 Inhibition in Ovarian Cancer
- (2011) Gottfried E. Konecny et al. CLINICAL CANCER RESEARCH
- Pattern of retinoblastoma pathway inactivation dictates response to CDK4/6 inhibition in GBM
- (2010) W. R. Wiedemeyer et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now